
Claims

1. Use of the compound of Formula A (or a pharmaceutically acceptable salt and/or solvate thereof) in the manufacture of a medicament for the treatment of bradykinin-mediated angioedema non-hereditary (BK-AEnH) on-demand, wherein the compound of Formula A (or a pharmaceutically acceptable salt and/or solvate thereof) is to be orally administered to a patient in need thereof on-demand,



Formula A.

2. The use according to claim 1,

wherein the compound of Formula A (or a pharmaceutically acceptable salt and/or solvate thereof) is for use in treating an acute attack of bradykinin-mediated angioedema non-hereditary (BK-AEnH) on-demand and is to be orally administered on-demand upon recognition of a symptom of an acute BK-AEnH attack.

3. The use according to claim 2,

wherein the symptom of an acute BK-AEnH attack recognised is at least one of: swelling of tissues; fatigue; headache; muscle aches; skin tingling; abdominal pain; nausea; vomiting; diarrhoea; difficulty swallowing; hoarseness; shortness of breath; and/or mood changes.

4. The use according to any one of claims 2 to 3,

wherein the compound of Formula A (or a pharmaceutically acceptable salt and/or solvate thereof) is to be orally administered on-demand within 1 hour of the symptom of an acute BK-AEnH attack being recognised.

5. The use according to any one of claims 2 to 4,

Wherein the compound of Formula A (or a pharmaceutically acceptable salt and/or solvate thereof) is to be orally administered on-demand within 30 minutes, within 20 minutes, within 10 minutes, or within 5 minutes of the symptom of an acute BK-AEnH attack being recognised.

6. The use according to any one of claims 2 to 5,

wherein the compound of Formula A (or a pharmaceutically acceptable salt or solvate thereof) is to be orally administered on-demand in the prodromal phase of an acute BK-AEnH attack.

7. The use according to claim 6,

wherein the symptom recognised is at least one of: a slight swelling, abdominal pain or reddening of the skin.

8. The use according to claim 7,

wherein the symptom recognised is erythema marginatum.

9. The use according to any one of claims 1 to 8,

wherein the treatment shortens the duration of the acute BK-AEnH attack.

10. The use according to claim 6,

wherein the treatment prevents the acute BK-AEnH attack from progressing to the swelling stage of an acute BK-AEnH attack.

11. The use according to claim 1,

wherein the compound of Formula A (or a pharmaceutically acceptable salt and/or solvate thereof) is to be orally administered on-demand to prophylactically reduce the likelihood of an acute BK-AEnH attack.

12. The use according to claim 11,

wherein the compound of Formula A (or a pharmaceutically acceptable salt and/or solvate thereof) is to be orally administered on-demand when it is anticipated that an acute BK-AEnH attack will be induced.

13. The use according to any one of claims 11 to 12,

wherein the compound of Formula A (or a pharmaceutically acceptable salt and/or solvate thereof) is to be orally administered on-demand to prevent an acute BK-AEnH attack.

14. The use according to any one of claims 12 to 13,

wherein the compound of Formula A (or a pharmaceutically acceptable salt and/or solvate thereof) is to be orally administered on-demand when it is anticipated that an acute BK-AEnH attack will be induced by physical traumata and/or stress.

15. The use according to claim 14,

wherein it is anticipated that an acute BK-AEnH attack will be induced by the physical traumata of a dental procedure and/or the mental stress associated with a dental procedure.

16. The use according to any one of the preceding claims,

wherein the compound (or a pharmaceutically acceptable salt and/or solvate thereof) is to be administered as an oral dosage form comprising: (i) the compound (or a pharmaceutically acceptable salt and/or solvate thereof), and (ii) pharmaceutically acceptable excipients.

17. The use according to claim 16,

wherein the oral dosage form is a tablet comprising microcrystalline cellulose as a diluent, croscarmellose sodium as a disintegrant, polyvinyl pyrrolidone as a binder, and optionally magnesium stearate as a lubricant.

18. The use according to any one of the preceding claims,

wherein the compound (or a pharmaceutically acceptable salt and/or solvate thereof) (i) inhibits plasma kallikrein, (ii) reduces cleavage of plasma prekallikrein, and/or (iii) reduces the generation of Factor XIIa from Factor XII.

19. The use according to claim 18,

wherein the patient is to be administered a dose of the compound of Formula A (or a pharmaceutically acceptable salt and/or solvate thereof) such that the patient's plasma has a concentration of the compound of Formula A (or a pharmaceutically acceptable salt and/or solvate thereof) of at least 500 ng/mL.

20. The use according to claim 19,

wherein the patient is to be administered at least 60 mg of the compound of Formula A (or a pharmaceutically acceptable salt and/or solvate thereof).

21. The use according to any one of the preceding claims,

wherein the compound of Formula A (or a pharmaceutically acceptable salt and/or solvate thereof) blocks contact system activation for up to six hours.

22. The use according to any one of the preceding claims,

wherein the compound of Formula A (or a pharmaceutically acceptable salt and/or solvate thereof) is to be administered at a daily dosage amount of between 5 mg and 2000mg.

23. The use according to any one of the preceding claims,

wherein the compound of Formula A is to be administered at a daily dosage amount of between 100 mg and 1500 mg, between 300 mg to 1800 mg, between 100 mg and 1400 mg per day, between 200 mg and 1200 mg, between 300 mg and 1200 mg, between 600 mg and 1200 mg, between 450 mg and 900 mg, between 500 mg and 1000 mg, between 450 mg and 600 mg, between 500 mg and 700 mg, between 800 mg and 1000 mg per day, between 900 mg and 1400 mg, or between 900 mg and 1200 mg.

24. The use according to any one of claims 22 to 23,

wherein the patient is to be administered the daily dosage amount in two dosage amounts within a 24 hour period starting from the time of taking the first dosage amount.

25. The use according to claim 24,

wherein the two dosage amounts are to be

administered simultaneously, separately or sequentially.

26. The use according to any one of claims 24 to 25,

wherein the second dosage amount is to be administered between 2 and 6 hours of the first, preferably between about 3 and 6 hours of the first dosage amount.

27. The use according to any one of claims 24 to 25,

wherein the second dosage amount is to be administered at least about 6 hours after the first dosage amount.

28. The use according to any one of claims 1 to 23,

wherein the patient is to be administered the compound of Formula A (or a pharmaceutically acceptable salt and/or solvate thereof) as three dosage amounts per day.

29. The use according to claim 28,

wherein the three dosage amounts are to be administered simultaneously, separately or sequentially.

30. The use according to any one of claims 28 to 29,

wherein the second and third dosage amounts are to be administered at least about 6 hours after the preceding dosage amount.

31. The use according to any one of claims 22 to 30,

wherein each dosage amount comprises about 600 mg of the compound of formula A.

32. The use according to claim 31,

wherein each dosage amount is to be administered as two tablets each comprising about 300 mg of the compound of formula A.

33. The use according to any one of the preceding claims,

wherein the bradykinin-mediated angioedema non-hereditary (BK-AEnH) is not caused by an inherited genetic dysfunction, fault, or mutation.

34. The use according to claim 33,

wherein the BK-AEnH is selected from: non-hereditary angioedema with normal C1 Inhibitor (AE-nC1 Inh), which can be environmental, hormonal, or drug-induced; acquired angioedema; anaphylaxis associated angioedema; angiotensin converting enzyme (ACE) inhibitor-induced angioedema; dipeptidyl peptidase-4 inhibitor-induced angioedema; and tPA-induced angioedema (tissue plasminogen activator-induced angioedema).

35. The use according to claim 33,

wherein, the AE-nC1 Inh is environmentally-induced by air pollution and/or silver nanoparticles.

36. The use according to any one of claims 11 to 13,

wherein the BK-AEnH is tPA-induced angioedema,

wherein the patient is also being administered a tissue plasminogen activator,

wherein the compound of Formula A (or a pharmaceutically acceptable salt and/or solvate thereof) is to be administered prior to, during, or after administration of the tissue plasminogen activator to the patient.